Abstract: There is provided with a method for treating cancer, comprising administering a pharmaceutical composition to a patient with cancer in combination with an anti-cancer agent, the pharmaceutical composition. A compound is represented by General Formula (I) or a pharmaceutically acceptable salt thereof: where R1 is an acyl residue from a fatty acid.

Abstract: A cyanide-free gold electroplating solution for forming gold deposits contains bismuth and compact-packed via-filling deposit with a U-shaped stacked structure in cross section inside drilled holes. A gold electroplating solution includes 15 g/L of gold (I) sodium sulfite (as gold element), 15 g/L of sodium sulfate, 50 g/L of sodium sulfite, 10 mg/L of thallium formate (as thallium element), 50 mg/L of bismuth nitrate (as bismuth element) and 1 g/L of sodium phosphate.

Abstract: [Problem] A compound which is useful as a STING inhibitor is provided. [Means for Solution] The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory action on STING and can be used as an agent for treating an autoimmune disease, a neurodegenerative disease, a type I interferonopathy and/or other STING-mediated disease.

Abstract: [Problem] A compound which is useful as a STING inhibitor is provided. [Means for Solution] The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory action on STING and can be used as an agent for treating an autoimmune disease, a neurodegenerative disease, a type I interferonopathy and/or other STING-mediated disease.

Abstract: The present invention addresses the problem of providing a pharmaceutical composition, in particular a compound suitable for prevention and/or treatment of an inflammatory disease and/or a neurodegenerative disease. The inventors of the present invention conducted extensive studies to find a compound that has suppressive action on NLRP3 inflammasome activation, and found that a substituted pyridazine compound has suppressive action on NLRP3 inflammasome activation, leading to completion of the present invention. The substituted pyridazine compound according to the present invention is expected to serve as a drug for prevention and/or treatment of an inflammatory disease and/or a neurodegenerative disease.

Abstract: Methods for stimulating the growth of non-leguminous plants are disclosed. In the methods, a non-leguminous plant, a part thereof, or a seedling or seed thereof is contacted with a composition comprising a chitooligosaccharide (CO) having the formula: R1 is —H, —CH3, —COCH3, —SO3H, —SO3Na, arabinose, methylated arabinose, fucose, or methylated fucose; R2 is —H, —CH3, —COCH3, —SO3H, —SO3Na, arabinose, methylated arabinose, fucose, or methylated fucose; each R3 is independently —H or —COCH3; and n is 0, 1, 2, 3, 4, 5 or 6. As non-limiting examples, the method can be used to stimulate production and yield in a cereal grain crop plant, such as rice, wheat or corn (maize).

Abstract: Methods for stimulating the growth of non-leguminous plants are disclosed. In the methods, a non-leguminous plant, a part thereof, or a seedling or seed thereof is contacted with a composition comprising a chitooligosaccharide (CO) having the formula: R1 is —H, —CH3, —COCH3, —SO3H, —SO3Na, arabinose, methylated arabinose, fucose, or methylated fucose; R2 is —H, —CH3, —COCH3, —SO3H, —SO3Na, arabinose, methylated arabinose, fucose, or methylated fucose; each R3 is independently —H or —COCH3; and n is 0, 1, 2, 3, 4, 5 or 6. As non-limiting examples, the method can be used to stimulate production and yield in a cereal grain crop plant, such as rice, wheat or corn (maize).

Abstract: Provided is a novel compound which is an agent for treating rejection reactions in various organ transplantations, allergy diseases, autoimmune diseases, and hematologic tumor, and based on a PI3K? selective inhibitory action and/or an IL-2 production inhibitory action and/or a B cell proliferation inhibitory action (including an activation inhibitory action). The provided compound has a PI3K? selective inhibitory action, an IL-2 production inhibitory action, and/or a B cell proliferation inhibitory action, including an activation inhibitory action.

Abstract: Provided is a triarylcarboxylic acid derivative, or an isomer, a prodrug, a hydrate, a solvate, a polymorph, or a pharmaceutically acceptable salt thereof, represented by the following general formula (I): wherein A is an optionally substituted aryl or heteroaryl, and B is an optionally substituted monocyclic heteroaryl; and a pharmaceutical composition comprising the same and a pharmaceutically acceptable carrier. The triarylcarboxylic acid derivative (I) exhibits potent xanthine oxidase inhibiting action and is therefore useful as a therapeutic agent for preventing or treating hyperuricemia, gout, inflammatory bowel disease, diabetic nephropathy and diabetic retinopathy.

Abstract: Provided is a triarylcarboxylic acid derivative, or an isomer, a prodrug, a hydrate, a solvate, a polymorph, or a pharmaceutically acceptable salt thereof, represented by the following general formula (I): wherein A is an optionally substituted aryl or heteroaryl, and B is an optionally substituted monocyclic heteroaryl; and a pharmaceutical composition comprising the same and a pharmaceutically acceptable carrier. The triarylcarboxylic acid derivative (I) exhibits potent xanthine oxidase inhibiting action and is therefore useful as a therapeutic agent for preventing or treating hyperuricemia, gout, inflammatory bowel disease, diabetic nephropathy and diabetic retinopathy.

Abstract: A differential amplifier circuit comprising a pair of input MOS transistors, wherein inputs are supplied to the gates thereof, load circuits are connected to the drains thereof, and a current source is connected to the sources thereof, the current value of the current source is altered in line with variations in the characteristics of the input MOS transistors, thereby suppressing variations in the output level generated at the drain terminals of the input MOS transistors. In other words, unlike a conventional differential amplifier circuit, the current value of the current source is not kept to a uniform value, but rather is altered in accordance with the transistor characteristics generated by the manufacturing process.

Abstract: A differential amplifier circuit comprising a pair of input MOS transistors, wherein inputs are supplied to the gates thereof, load circuits are connected to the drains thereof, and a current source is connected to the sources thereof, the current value of the current source is altered in line with variations in the characteristics of the input MOS transistors, thereby suppressing variations in the output level generated at the drain terminals of the input MOS transistors. In other words, unlike a conventional differential amplifier circuit, the current value of the current source is not kept to a uniform value, but rather is altered in accordance with the transistor characteristics generated by the manufacturing process.

Abstract: A differential amplifier circuit comprising a pair of input MOS transistors, wherein inputs are supplied to the gates thereof, load circuits are connected to the drains thereof, and a current source is connected to the sources thereof, the current value of the current source is altered in line with variations in the characteristics of the input MOS transistors, thereby suppressing variations in the output level generated at the drain terminals of the input MOS transistors. In other words, unlike a conventional differential amplifier circuit, the current value of the current source is not kept to a uniform value, but rather is altered in accordance with the transistor characteristics generated by the manufacturing process.